Cancer News and Research RSS Feed - Cancer News and Research Twitter

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Treatment plans may include surgery, radiation and/or chemotherapy.
Study assesses effectiveness of UK-wide screening programme for Lynch Syndrome

Study assesses effectiveness of UK-wide screening programme for Lynch Syndrome

Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers, new research has found. [More]
Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer. [More]
Research!America to recognize distinguished research advocates with Advocacy Awards

Research!America to recognize distinguished research advocates with Advocacy Awards

Research!America's 19th annual Advocacy Awards will honor distinguished research advocates who are trailblazers in advancing medical progress to improve the health and economic security of our nation. The event will take place on Wednesday, March 11, 2015, at the Andrew W. Mellon Auditorium in Washington, DC. [More]
Research finding opens door to potential treatment for MPS IIIB

Research finding opens door to potential treatment for MPS IIIB

MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death -- often before reaching adulthood. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

Cancer community joins coalition seeking Medicare coverage for CT lung cancer screening

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer. [More]
PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid. [More]
Finding ways to rejuvenate "immunological age" of the brain

Finding ways to rejuvenate "immunological age" of the brain

How the brain ages is still largely an open question - in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. [More]
Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal. [More]
CFDA clears Elekta's Versa HD radiation therapy system

CFDA clears Elekta's Versa HD radiation therapy system

Following US and European approvals of Elekta's Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country. [More]
Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Aspen Dental expands operations with a new dental office in Hermitage, Tennessee

Aspen Dental expands operations with a new dental office in Hermitage, Tennessee

A new Aspen Dental office is opening in Hermitage, TN on Thursday, October 2. Located at 4054 Lebanon Pike, the conveniently located practice will provide dental services that range from implant services and dentures to general dentistry and restoration. [More]
New approach to solve global challenges in food security, emerging diseases and biodiversity loss

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences. [More]
Novel project to develop new models of care for depression in older adults

Novel project to develop new models of care for depression in older adults

UC Davis and the University of Washington are implementing a project to develop innovative new models of care for depression in older adults through a $2.5 million grant from the California-based Archstone Foundation, a private grant-making organization whose mission is to contribute toward the preparation of society in meeting the needs of an aging population. [More]
Antibiotic exposure in infancy linked to childhood obesity

Antibiotic exposure in infancy linked to childhood obesity

Repeated exposure to broad-spectrum antibiotics in the first two years of life is associated with early childhood obesity, say researchers from The Children's Hospital of Philadelphia in a retrospective study based on data from electronic health records from the extensive CHOP Care Network. [More]
New Aspen Dental office opened in Sebring, Florida

New Aspen Dental office opened in Sebring, Florida

A new Aspen Dental office is opening in Sebring, FL on Thursday, October 2. Located at 1855 US 27 North, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration. [More]
Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Guerbet wins Drug Shortage Assistance Award from FDA

Guerbet wins Drug Shortage Assistance Award from FDA

Guerbet, a pioneer in the field of contrast agents for medical imaging, has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration for its assistance in preventing or alleviating a drug shortage. [More]
Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma. [More]